Device therapies such as intragastric balloon, endoscopic sleeve gastroplasty or vagal nerve blockade are generally less effective weight loss strategies than surgical intervention, but provide 1424% excess weight loss when used in the treatment of obesity [23]
Retatrutide activates all three: GLP-1, which helps regulate appetite, fullness, insulin release, and blood sugar GIP, which plays a role in insulin signaling, metabolism, and appetite Glucagon, which may increase energy expenditure and support fat metabolism Early phase 3 trial data reported an average weight loss of 28.7% at 68 weeks, a figure that would represent a meaningful jump beyond current options
Oral supplements rely on the digestive system, which limits how much your body can actually absorb
Work in a clean, low-dust environment
National Institutes of Health Office of Dietary Supplements 2021